| Name | Title | Contact Details |
|---|
At Prosperity Bank, we believe in a community banking philosophy where personal relationships and great experiences go hand-in-hand. We provide convenient technology options that our customers expect – all backed by the highest level of security. At every touch point, youll find knowledgeable associates ready to serve our customers with accuracy and a smile time and time again. Prosperity provides personal banking services and investments to consumers and small to medium sized businesses throughout Texas and Oklahoma. Founded in 1983, Prosperity ranks among the top 100 U.S. banks in assets. Member FDIC. Equal Housing Lender.
Preco, LLC is a premier provider of solutions for material processing needs. We are a leading designer and manufacturer of high-speed and high-accuracy automated processing systems. In addition, Preco is a skilled laser integrator offering cutting, perforating, welding, and other specialized industrial processing applications. With our proprietary die cutting and laser-based manufacturing capabilities, we are one of the largest contract manufacturing service (CMS) providers in North America offering laser cutting, scoring, perforating, welding, cladding, treat heating and die cutting services.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Compello Partners is an M&A consulting firm that provides technology, operations and security services to private equity firms, corporations and their portfolio companies. We are strategic operators that conduct pre-acquisition due diligence and post-acquisition services for types such as carve-outs, merger integrations, portfolio transformations, add-on`s, turnarounds and restructuring, sell-side preparedness, and digital transformations utilizing artificial intelligence/robotic process automation.